Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study.

Karin CernaDana DuricovaMartin LukasNadezda MachkovaVeronika HrubaKatarina MitrovaKristyna KubickovaMarta KostrejovaVladimir TeplanMartin VasatkoKristyna KastylovaMilan Lukas

Published in: Inflammatory bowel diseases (2021)

Our findings warrant particular attention to the anti-SARS-CoV-2 vaccination of IBD patients treated with TNF-α inhibitors with concomitant immunomodulators and show the priority of mRNA vaccines in this specific group of patients.

Keyphrases

sars cov
patients with inflammatory bowel disease
end stage renal disease
ejection fraction
chronic kidney disease
prognostic factors
binding protein